Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Comment by balainon Jul 21, 2022 4:14pm
155 Views
Post# 34841533

RE:Market Rotation

RE:Market RotationOnce again inventors, why are you drooling at the prospects of phase 1 results when it took the company 24 years to get multiple products approved, completed phase 3, completed phase 2 and so forth, just to get rid of them for peanuts and start fresh with pre-clinical products?

Even Pritchard and Sartore must be wondering what flavour and how much of it you're smoking, but I'm sure they don't mind having one cheerleader left as they draw their salaries waiting for the saga to finally die...




<< Previous
Bullboard Posts
Next >>